Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Barbara Bortot,Maurizio Mongiat,Erica Valencic,Simeone Dal Monego,Danilo Licastro,Matteo Crosera,Gianpiero Adami,Enrico Rampazzo,Giuseppe Ricci,Federico Romano,Giovanni Maria Severini,Stefania Biffi +11 more
TLDR
It is found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug and contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivo.Abstract:
Background Platinum resistance is a major challenge in the management of ovarian cancer Even low levels of acquired resistance at the cellular level lead to impaired response to cisplatin In ovarian cancer intraperitoneal therapy, nanoparticle formulation can improve the cisplatin's pharmacokinetics and safety profile Purpose This work aimed to investigate the chemo-sensitivity of ovarian cancer SKOV3 cells upon short-term (72h) single treatment of cisplatin and cisplatin-loaded biodegradable nanoparticles (Cis-NP) The aim was then to determine the therapeutic properties of Cis-NP in vivo using a SKOV3-luc cells' xenograft model in mice Methods Cell cytotoxicity was assessed after the exposure of the cell culture to cisplatin or Cis-NP The effect of treatments on EMT and CSC-like phenotype was studied by analyzing a panel of markers by flow cytometry Intracellular platinum concentration was determined by inductively coupled plasma mass spectrometry (ICS-MS), and gene expression was evaluated by RNAseq analysis The efficacy of intraperitoneal chemotherapy was evaluated in a SKOV3-luc cells' xenograft model in mice, through a combination of bioluminescence imaging, histological, and immunohistochemical analyses Results We observed in vitro that short-term treatment of cisplatin has a critical role in determining the potential induction of chemoresistance, and a nanotechnology-based drug delivery system can modulate it The RNAseq analysis underlines a protective effect of nanoparticle system according to their ability to down-regulate several genes involved in chemoresistance, cell proliferation, and apoptosis The highest intracellular platinum concentration obtained with Cis-NP treatment significantly improved the efficacy Consistent with in vitro results, we found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug Conclusion Nanoparticle-mediated cisplatin delivery may serve as an intracellular depot impacting the cisplatin pharmacodynamic performance at cellular levels These features may contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivoread more
Citations
More filters
Journal ArticleDOI
Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance.
Yanhua Zhang,Yang Dong,Hao Fu,Hui Huang,Zhihua Wu,Meng Zhao,Xupeng Yang,Qianqian Guo,Yourong Duan,Ying Sun +9 more
TL;DR: NPs-cRGD with ultrasound promoted the apoptosis of resistant ovarian cancer cells by multiple mechanisms, including increased cellular drug accumulation, reversed antiapoptotic effects by siBIRC5, and enhanced ROS levels.
Journal ArticleDOI
Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer
Muhammad Hadi Sultan,Sivakumar Sivagurunathan Moni,Osama Madkhali,Mohammed Ali Bakkari,Saeed Alshahrani,Saad S. Alqahtani,Nabil A. Alhakamy,Syam Mohan,Mohammed Ghazwani,Haitham Bukhary,Yosif Almoshari,Ahmad Salawi,Meshal Fahad M Alshamrani +12 more
TL;DR: In this paper , the authors developed cisplatin-loaded chitosan nanoparticles (CCNP) and mAbCCNP as targeted delivery formulations, which exhibited significant physicochemical properties.
Journal ArticleDOI
Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer
Muhammad Hadi Sultan,Sivakumar Sivagurunathan Moni,Osama Madkhali,Mohammed Ali Bakkari,Saeed Oudah Alshahrani,Saad S. Alqahtani,Nabil A. Alhakamy,Syam Mohan,Mohammed Ghazwani,Haitham Bukhary,Yosif Almoshari,Ahmad Salawi,Meshal Fahad M Alshamrani +12 more
TL;DR: In this article , the authors developed cisplatin-loaded chitosan nanoparticles (CCNP) and mAbCCNP as targeted delivery formulations, which exhibited significant physicochemical properties.
Journal ArticleDOI
Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles
Atena Abed,Maryam Derakhshan,Merat karimi,Matin Shirazinia,Maryam Mahjoubin-Tehran,M. Homayonfal,Michael R. Hamblin,Seyed Abbas Mirzaei,Hamidreza Soleimanpour,Sadegh Dehghani,F. Farzaneh Dehkordi,Hamed Mirzaei +11 more
TL;DR: The development of PtNPs as an anticancer agent is one of the most valuable approaches for cancer treatment and holds great promise, especially in the area of disease diagnosis, early detection, cellular and deep tissue imaging, drug/gene delivery, as well as multifunctional therapeutics.
Journal ArticleDOI
Potential of curcumin-loaded cubosomes for topical treatment of cervical cancer.
Francesca Damiani Victorelli,Livia Salvati Manni,Stefania Biffi,Barbara Bortot,Hilde Harb Buzzá,Viviane Lutz-Bueno,Stephan Handschin,Giovana Maria Fioramonti Calixto,Sergio Murgia,Marlus Chorilli,Raffaele Mezzenga +10 more
TL;DR: In this article , the authors developed a platform for vaginal administration of lipophilic drugs for cervical cancer treatment and evaluated their potential efficiency using the CAM (chick embryo chorioallantoic membrane) model.
References
More filters
Journal ArticleDOI
Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
Alaa A Elzarkaa,Waleed Shaalan,Doaa El-Emam,Hassan Mansour,Mahmoud Melis,Eduard Malik,Amr A. Soliman +6 more
TL;DR: It is concluded that the PCI score is a reliable tool helping to assess the extent of disease in advanced serous EOC patients and may help predicting complete surgical cytoreduction but cannot qualify as a predictor of survival.
Journal ArticleDOI
The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors.
TL;DR: It is concluded that several DNA/histone-modifying enzymes and chromatin remodelers may serve as biomarkers for subtyping, dictating prognosis and survival, and, possibly, for serving as targets of directed, less toxic therapies.
Journal ArticleDOI
Nanoparticles and the immune system: challenges and opportunities
TL;DR: This work has recognized that nonspecific immune activation, for example, by administering immune checkpoint inhibitors, can reactivate natural immunity that apparently evolves spontaneously during the cancer development and progression, and may result in impressive and durable remissions in some cancer entities.
Journal ArticleDOI
Evaluation of satisfaction with three different cervical cancer screening modalities: clinician-collected Pap test vs. HPV test by self-sampling vs. HPV test by urine sampling
Hye Young Shin,Bomyee Lee,Sang-Hyun Hwang,Dong Ock Lee,Na Young Sung,Jae Young Park,Jae Kwan Jun +6 more
TL;DR: Korean women were more likely to report satisfaction with alternative modalities (self-sampling and urine sampling) for CCS in comparison to the Pap test, which suggests that self-collected modalities may help with improving CCS uptake rates by eliminating burden related with the Pap Test.
Journal Article
Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
Stephen B. Howell,Salman Kirmani,Edward F. McClay,Sinil Kim,Patricia S. Braly,Steven C. Plaxe +5 more
TL;DR: The results of these trials are consistent with the hypothesis that increased drug delivery will result in higher response rates and improved survival, and data are sufficiently encouraging to mandate phase III randomized trials of this program.